GET DAILY SIGNALSTeleflex (TFX) Q3 2026 Earnings Preview: Navigating Transformation and Expectations
Key Takeaways
- Teleflex Incorporated is scheduled to report its third quarter 2026 results before the market opens on Thursday, November 5, 2026, with a conference call at 8:00 a.m. ET.
- Wall Street consensus points to adjusted earnings of roughly $1.90 per share on revenue of about $565 million for the quarter ended September 30, 2026.
- The medical device maker is mid-transformation, having completed its OEM (original equipment manufacturer) divestiture while integrating the acquired Biotronik Vascular Intervention business.
- In the prior quarter, Teleflex posted adjusted earnings of $1.76 per share on revenue of $570.3 million, beating expectations.
- Full-year 2026 guidance calls for adjusted earnings per share of $6.90 to $7.20 and pro forma adjusted constant currency revenue growth of 3.5% to 4.5%.
Earnings Context and Why It Matters
Teleflex is in the middle of one of the most significant repositionings in its history. The company has sold its OEM business, agreed to divest its Acute Care and Interventional Urology units, and pivoted toward a focused portfolio built around Vascular Access, Interventional, and Surgical products. This quarter's report is a key checkpoint for investors gauging whether new Chief Executive Officer Jason Weidman can restore execution momentum and justify a potential re-rating of the stock. Because the company reports under a standard calendar fiscal year, the September quarter is its third quarter of 2026, and results will reflect the early payoff from its capital-allocation and cost-discipline initiatives. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Analysts expect Teleflex to deliver adjusted earnings of approximately $1.90 per share on revenue of roughly $565 million for the third quarter of 2026. These figures follow a second quarter in which the company generated revenue from continuing operations of $570.3 million, up 28.9% year over year on a reported basis and up 4.7% on a pro forma adjusted constant currency basis, alongside adjusted earnings per share (EPS) of $1.76 that came in ahead of consensus.
Investors will be watching several metrics closely. Pro forma adjusted constant currency revenue growth is the clearest read on organic demand, given the noise created by divestitures and the Vascular Intervention acquisition. Margin trends also matter: management has flagged roughly $90 million of stranded costs in 2026, with adjusted operating margin expected around 19% before transition-services benefits arrive. Commentary on guidance will be pivotal, since the company tightened its full-year outlook in August, lowering revenue-growth expectations while raising its adjusted EPS range.
Market Reaction and Investor Sentiment
Sentiment heading into this report is cautiously optimistic but watchful. TFX shares have drawn attention from analysts focused on the turnaround, with at least one major firm upgrading the stock to a Buy rating in late September. Yet the company has a history of sharp post-earnings moves, and the second quarter's results were followed by a notable stock decline as investors weighed elongated integration timelines for the Vascular Intervention business against stronger-than-expected earnings. Key risk factors this quarter include the pace of integration, foreign-exchange headwinds, and any evidence that margin pressure is lingering longer than expected. A clear signal on the divestiture pipeline and cost discipline will likely drive the immediate reaction.
Forward Outlook and Key Factors to Monitor
Looking beyond the third quarter, the central question is whether Teleflex can translate its portfolio reshaping into durable, higher-margin growth. Management has emphasized that many of 2026's margin pressures, including stranded costs and integration disruption, are expected to be temporary and to ease as transition-services and manufacturing-services agreements take effect.
Investors should monitor the completion of the remaining divestitures of the Acute Care and Interventional Urology businesses, which are expected to close in the second half of 2026. The company has said it plans to use the majority of the net proceeds to repurchase stock under its $1 billion authorization and to pay down roughly $800 million of debt, moves that could meaningfully lift adjusted EPS over time.
On the innovation front, watch for updates on Freesolve, the drug-eluting resorbable magnesium scaffold, and on EZPLAZ freeze-dried plasma, which recently received U.S. Food and Drug Administration approval. These programs represent long-term growth optionality but are unlikely to affect near-term results. Overall, the focus remains on execution, integration milestones, and whether guidance can be sustained without further downward revisions.
Using Tickeron’s AI Screener for Research
In preparing for earnings season, I turned to Tickeron’s AI Screener to quickly filter medical device peers and review technical patterns alongside fundamentals. The tool surfaces relevant opportunities efficiently by combining customizable criteria like industry, volatility, and AI signals, which helps me cross-check ideas without spending hours on manual scans. It serves as a practical addition to my regular workflow when evaluating names like TFX ahead of key reports.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TFX's RSI Indicator ascending out of oversold territory
The RSI Oscillator for TFX moved out of oversold territory on September 28, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 41 similar instances when the indicator left oversold territory. In 28 of the 41 cases the stock moved higher. This puts the odds of a move higher at 68%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on TFX as a result. In 49 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
The Moving Average Convergence Divergence (MACD) for TFX just turned positive on October 01, 2026. Looking at past instances where TFX's MACD turned positive, the stock continued to rise in 28 of 51 cases over the following month. The odds of a continued upward trend are 55%.
Following a +5.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where TFX advanced for three days, in 165 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
TFX moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TFX crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TFX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
TFX broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TFX entered a downward trend on October 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.902) is normal, around the industry mean (4.952). P/E Ratio (-5.657) is within average values for comparable stocks, (36.644). Projected Growth (PEG Ratio) (0.165) is also within normal values, averaging (4.143). Dividend Yield (0.010) settles around the average of (0.005) among similar stocks. P/S Ratio (2.508) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. TFX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TFX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
How Does My Retirement Age Impact My Social Security Benefits?
What is currency substitution?
Will My Pension Payments Affect My Social Security Payments?
What do meme stocks refer to, and can they be considered genuine investments?
AI Trading Bots: Ticker-Centric Swing Traders, Virtual Accounts, on January 28, 2025
General Information
a provider of medical devices for critical care, urology and surgery
Industry PharmaceuticalsOther
Advertisement